1. In Vivo
  2. >>Growth
  3. >>VC Playbook

Astellas’s Venture Arm Is Focused On Flexibility But Avoiding Hype

 
• By Lucie Ellis-Taitt

VC Playbook: Bradley Hardiman, senior director of business development at Astellas Venture Management, discusses setting a CVC strategy when the biopharma market is in a “state of flux.”  

Greenshoots
Hardiman is seeing 'green shoots of recovery' in the biopharma market • Source: Shutterstock

“We've got geopolitical pressures, macro-economic pressures, interest rates, inflation…” Bradley Hardiman, senior director of business development at Astellas Venture Management, listed the challenges for biopharma going into 2024. “But as an industry, we've always had something that challenges us, and we've always overcome it,” he told In Vivo on the sidelines of the recent BIO-Europe conference in Munich, Germany.

Hardiman was previously an investor at Spex Capital before joining Astellas in April 2022, initially in the company’s internal business...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from VC Playbook

In Conversation With Foundation Fighting Blindness

 
• By David Wild

Jason Menzo, CEO of the Foundation Fighting Blindness, says the organization is adapting its funding strategy, navigating regulatory challenges and accelerating the translation of academic discoveries into industry-led clinical development.

In Conversation: Sketching The Future Of Biotech Investment With Lilly Ventures

 
• By Jo Shorthouse

Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.

TechBio’s Next Wave: Where AI Meets Biology And Investment Opportunity

 
• By David Wild

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

Mixed Bag For Biopharma Funding In 2025: Dispatches From J.P. Morgan, Biotech Showcase

 
• By Mandy Jackson

The J.P. Morgan Healthcare Conference and Biotech Showcase revealed what investors are really thinking about the health of the capital markets this year.

More from Growth

Deals In Depth: May 2025

 
• By Maureen Riordan and Deanna Kamienski

Seven $1bn+ alliances were penned in May, and four exceeded $2bn.

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.